Has Michael Wertheim, MD received payments from drug or device companies?

Yes. Drug and device makers reported $783,074 in general payments to Michael Wertheim, MD across 1,167 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Wertheim, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Wertheim, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Wertheim, MD

Hematology & Oncology · Fort Myers, FLNPI 1982643474

Payments from drug & device makers

$783,074in general payments, 2019–2025

Across 1,167 payments — averaging $671.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

EMD Serono, Inc.$445K
Array Biopharma Inc$125K
E.r. Squibb & Sons, L.L.C.$77K
Janssen Research & Development, LLC$29K
AstraZeneca$24K
Incyte Corporation$18K
plus $65K from 54 others

What the payments were for

Consulting fees$19,32218%
Speaking & faculty fees$68,82865%
Travel & lodging$1,6032%
Food & beverage$14,63514%
Education$5731%
Other$1,2801%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
EMD Serono, Inc.	174	$444,698
Array Biopharma Inc	39	$124,790
E.r. Squibb & Sons, L.L.C.	42	$77,282
Janssen Research & Development, LLC	10	$29,147
AstraZeneca(2 entities)	93	$24,024
Incyte Corporation	22	$17,716
Genentech USA, Inc.	52	$9,062
Takeda Pharmaceuticals U.S.A., Inc.	24	$8,918
Seagen Inc.	34	$8,890
Amgen	52	$8,870
Bristol Myers Squibb	47	$5,611
Mirati Therapeutics, Inc.	20	$5,312
Astellas Pharma US Inc	17	$2,900
AbbVie	31	$1,781
Novartis	38	$1,684
Daiichi Sankyo Inc.	16	$1,528
Pfizer	129	$1,494
Beigene USA, Inc.	4	$1,427
Sanofi	52	$1,245
Bayer	17	$876
Merck	49	$752
Johnson & Johnson	22	$482
GSK	17	$457
Beigene, Ltd.	1	$450
Janssen Scientific Affairs, LLC	1	$350
Lilly USA, LLC	20	$330
Eisai Inc.	13	$243
Novocure GmbH	1	$200
Karyopharm Therapeutics Inc.	8	$180
Athenex Pharmaceutical Division, LLC	1	$175
Sobi, Inc	10	$174
Dova Pharmaceuticals	11	$172
Jazz Pharmaceuticals Inc.	9	$154
Puma Biotechnology, Inc.	8	$150
Gilead(2 entities)	10	$148
Exelixis Inc.	7	$131
Regeneron Healthcare Solutions, Inc.	6	$121
Comsort, Inc	1	$100
Coherus Oncology, Inc.	4	$89
Boehringer Ingelheim	5	$85
Ipsen Biopharmaceuticals, Inc	4	$72
Grifols USA, LLC	3	$65
AMAG Pharmaceuticals, Inc.	4	$63
G1 Therapeutics, Inc.	3	$61
Tolmar Pharmaceuticals, Inc.	4	$58
AVEO Pharmaceuticals, Inc.	2	$51
Taiho Oncology, Inc.	3	$51
Blueprint Medicines Corporation	2	$49
Tesaro, Inc.	3	$47
Agios Pharmaceuticals, Inc.	3	$44
Morphosys, US Inc.	2	$44
Pharmacyclics LLC, An Abbvie Company	2	$38
Sun Pharmaceutical Industries Inc.	2	$37
Aurobindo Pharma USA, Inc.	2	$29
Teva Pharmaceuticals USA, Inc.	1	$19
Foundation Medicine, Inc.	1	$19
Cumberland Pharmaceuticals, Inc.	1	$18
Mylan Institutional Inc.	1	$17
Acceleron Pharma, Inc.	1	$15
Kyowa Kirin, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

IMFINZI$17,985
NINLARO$8,473
ADCETRIS$8,384
Nplate$7,102
TECENTRIQ$6,289
KRAZATI$5,100
TAGRISSO$4,710
BRAFTOVI$4,363
MEKTOVI$4,363
OPDIVO$4,144
Abraxane$3,437
XTANDI$2,655
ROZLYTREK$2,125
TEVIMBRA$1,375
Venclexta$1,301
Revlimid$565
Pomalyst$565
CARVYKTI$474
BRUKINSA$450
DARZALEX$124

How this compares

$783,074 in reported general payments places this provider in the 80th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida →

Medicare billing

Part B allowed, 2024

$84,293

Medicare patients

109

Services billed

4,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Hydroxyurea	11	$313

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Fort Myers

Carl LandgrenMiami$47.8M
Julio ChavezTampa$16.4M
Steven AttiaJacksonville$13.9M
Santosh NairOrange City$13.5M
Frederick LockeTampa$12.8M
Tarek MekhailOrlando$11.2M
Carlos AlemanyOrlando$10.9M
Thomas GeorgeGainesville$10.3M
Sikander AilawadhiJacksonville$9.8M
Richard KimTampa$8.5M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →